The President and CEO of Alimera Sciences (ALIM), Rick Eiswirth, says that the company is developing prescription ophthalmology treatments for the management of retinal diseases with the primary product being Iluvien.
The Watch List
18 Mar 2021
SHARE
Futures
06 Jan 2022
The Watch List
05 Jan 2022
Market On Close
04 Jan 2022
Morning Trade Live
17 Mar 2022
The Watch List
22 Feb 2022
Morning Trade Live
04 Feb 2022